The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer

Autor: Anderson, Richard, Mansi, J, Coleman, R E, Adamson, D J A, Leonard, Robert
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: European Journal of Cancer
Anderson, R A, Mansi, J, Coleman, R E, Adamson, D J A & Leonard, R C F 2017, ' The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer ', European Journal of Cancer, vol. 87, pp. 58-64 . https://doi.org/10.1016/j.ejca.2017.10.001
Anderson, R, Mansi, J, Coleman, R E, Adamson, D J A & Leonard, R 2017, ' The utility of anti-müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer ', European Journal of Cancer . https://doi.org/10.1016/j.ejca.2017.10.001
ISSN: 1879-0852
0959-8049
DOI: 10.1016/j.ejca.2017.10.001
Popis: Aim Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy. Methods Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed. Women were assessed for premature ovarian insufficiency (POI: amenorrhoea with elevated follicle-stimulating hormone (FSH)) at 24 months after diagnosis. The accuracy of AMH for the diagnosis of POI and its prediction from measurement at the end of chemotherapy was calculated. Results AMH below the level of detection showed good diagnostic accuracy for POI at 24 months (n = 73) with receiver operating characteristic (ROC) area under the curve of 0.86, sensitivity 1.0 and specificity 0.73 at the assay limit of detection. In women aged >40 at diagnosis who did not receive goserelin, AMH measured at end of chemotherapy also gave good prediction of POI at 24 months (area under the curve (AUC) 0.89 95% CI 0.75–1.0, n = 32), with sensitivity 0.91, specificity 0.82, diagnostic odds ratio (DOR) 42.8. FSH gave slightly lower AUC, and specificity was low at 0.55. Age but not tamoxifen impacted on AMH levels. Conclusion Using this sensitive AMH assay, the finding of an undetectable AMH level in women aged >40 at the end of chemotherapy for eBC gave a good prediction that ovarian function would not return. This may allow alterations in post-chemotherapy endocrine management.
Highlights • Chemotherapy for early breast cancer results in permanent loss of ovarian function in some women. • We assessed the accuracy of measurement of anti-Müllerian hormone (AMH) at end of chemotherapy for prediction of this in women aged >40 at diagnosis. • AMH measured at end of chemotherapy gave good prediction of premature ovarian insufficiency (POI) at 24 months. • This may allow optimisation of subsequent endocrine treatment.
Databáze: OpenAIRE
Externí odkaz: